Semaglutide vs Tirzepatide:
Which is Right for You?

Detailed comparison of Semaglutide and Tirzepatide — mechanisms, dosing, side effects, costs, and best use cases.

⚠️ Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any peptide or medication protocol.

Quick Comparison

FactorSemaglutideTirzepatide
CategoryGLP-1 / Weight LossGLP-1 / Weight Loss
Common Dose250–2,400 mcg2,500–15,000 mcg
FrequencyOnce weeklyOnce weekly
Half-Life~7 days~5 days
Best ForWeekly GLP-1, 10+ year safety record, often more accessibleMaximum weight loss potential, superior clinical trial results

Semaglutide

GLP-1 / Weight Loss

Semaglutide is a GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy 2.4 mg/week). It works by mimicking GLP-1: increasing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and powerfully reducing appetite through...

Key Benefits

  • ~15% average body weight reduction
  • Powerful appetite suppression
  • Blood glucose control
  • Cardiovascular risk reduction

Dose: 250–2,400 mcg

Frequency: Once weekly

⚡ Semaglutide Calculator

Tirzepatide ★ Recommended

GLP-1 / Weight Loss

Tirzepatide (Mounjaro/Zepbound) is the first dual GIP/GLP-1 receptor agonist, producing superior weight loss vs semaglutide — averaging 20–22% body weight reduction in the SURMOUNT trials. By activating both GIP and GLP-1 receptors, it enhances insulin sensitivity, reduces appetite via dual hypothal...

Key Benefits

  • 20–22% average body weight reduction
  • Outperforms semaglutide in clinical trials
  • Dual GIP+GLP-1 mechanism
  • Improved insulin sensitivity

Dose: 2,500–15,000 mcg

Frequency: Once weekly

⚡ Tirzepatide Calculator

Which Should You Choose?

Tirzepatide's dual GIP+GLP-1 mechanism produces ~20-22% weight loss vs semaglutide's ~15%. Head-to-head trials confirm tirzepatide is more effective for weight loss.

About Semaglutide

Semaglutide is a GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy 2.4 mg/week). It works by mimicking GLP-1: increasing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and powerfully reducing appetite through brain receptors. Clinical trials showed average weight loss of 15% body weight over 68 weeks. Starting dose: 0.25 mg weekly, titrated every 4 weeks. Compounded semaglutide requires reconstitution with bacteriostatic water. Track your weekly doses and titration schedule with the DoseIQ app.

📖 Read Full Semaglutide Dosing Guide →

About Tirzepatide

Tirzepatide (Mounjaro/Zepbound) is the first dual GIP/GLP-1 receptor agonist, producing superior weight loss vs semaglutide — averaging 20–22% body weight reduction in the SURMOUNT trials. By activating both GIP and GLP-1 receptors, it enhances insulin sensitivity, reduces appetite via dual hypothalamic pathways, slows gastric emptying, and improves beta-cell function. FDA-approved for type 2 diabetes (Mounjaro) and weight management (Zepbound). Starting dose: 2.5 mg weekly, titrated every 4 weeks to 15 mg maximum. Track your tirzepatide titration schedule with the DoseIQ app.

📖 Read Full Tirzepatide Dosing Guide →

Frequently Asked Questions

Q: Which produces more weight loss?
A: Tirzepatide averages 20-22% vs semaglutide's 15% in clinical trials. Both are highly effective.
Q: Which has fewer side effects?
A: Similar GI side effects for both. Tirzepatide may have slightly more nausea at higher doses.
Q: Which is more expensive?
A: Tirzepatide is generally slightly more expensive than semaglutide in compounded form.

📱 Track Every Dose with DoseIQ

The #1 peptide tracking app for iPhone. Calculate doses, log injections, set reminders, and track your progress.

⬇️ Download Free on App Store